Enzalutamide in metastatic prostate cancer before chemotherapy.
暂无分享,去创建一个
F. Saad | J. Carles | H. Scher | K. Miller | A. Armstrong | C. Higano | B. Tombal | C. Sternberg | D. Rathkopf | P. Mainwaring | I. Davis | Choung-Soo Kim | D. Phung | Y. Loriot | S. Chowdhury | M. Taplin | P. Iversen | K. Fizazi | T. Beer | J. D. de Bono | G. Kimura | C. Evans | S. Bhattacharya | F. Perabo | A. Joshua | H. Mansbach | S. Noonberg | P. Venner | A. Armstrong | Cora N. Sternberg | Ian D Davis | Christopher P Evans | Anthony M Joshua | Ian D. Davis | Anthony M. Joshua
[1] L. Collette,et al. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. , 2014, European urology.
[2] A. Kibel. Differences in Time to Disease Progression Do Not Predict for Cancer-specific Survival in Patients Receiving Immediate or Deferred Androgen-deprivation Therapy for Prostate Cancer: Final Results of EORTC Randomized Trial 30891 with 12Years of Follow-up , 2014 .
[3] I Syndikus,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.
[4] P. Stattin,et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer , 2013, Acta oncologica.
[5] F. Saad,et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The New England journal of medicine.
[6] Kurt Miller,et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.
[7] C. Parker,et al. A population-based study of prostate cancer chemotherapy. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).
[8] F. Nathan,et al. Cancer Management and Research Dovepress Differences in Treatment Patterns among Patients with Castration-resistant Prostate Cancer Treated by Oncologists versus Urologists in a Us Managed Care Population , 2022 .
[9] J. D. de Bono,et al. Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients , 2011, Clinical Cancer Research.
[10] K. Fizazi,et al. Targeting Continued Androgen Receptor Signaling in Prostate Cancer , 2011, Clinical Cancer Research.
[11] Arturo Molina,et al. Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.
[12] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[13] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[14] J. Humm,et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.
[15] S. Glina,et al. Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V. Hodges. , 2010, The journal of sexual medicine.
[16] H. Scher,et al. Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.
[17] H. Scher,et al. Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.
[18] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[19] Susan Halabi,et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Jorge Yao,et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. , 2006, The Lancet. Oncology.
[21] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[22] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[23] T. Wilt,et al. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. , 2001, The Cochrane database of systematic reviews.
[24] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[25] M. Piérart,et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. , 1997, The New England journal of medicine.
[26] S. Holm. A Simple Sequentially Rejective Multiple Test Procedure , 1979 .
[27] C. Huggins,et al. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.